Gilhus NE, Tzartos S, Evoli A, Palace J, Burns TM, Verschuuren JJGM. Myasthenia gravis. Nat Rev Dis Prim. 2019;5(1):1–19. https://doi.org/10.1038/s41572-019-0079-y.

Article  Google Scholar 

Grob D, Arsura EL, Brunner NG, Namba T. The course of myasthenia gravis and therapies affecting outcome. Ann NY Acad Sci. 1987;505(1 Myasthenia Gr):472–99. https://doi.org/10.1111/j.1749-6632.1987.tb51317.x

Andersen JB, Gilhus NE, Sanders DB. Factors affecting outcome in myasthenia gravis. Muscle Nerve. 2016;54(6):1041–9. https://doi.org/10.1002/MUS.25205.

Article  CAS  PubMed  Google Scholar 

Carr AS, Cardwell CR, McCarron PO, McConville J. A systematic review of population based epidemiological studies in myasthenia gravis. BMC Neurol. 2010;10. https://doi.org/10.1186/1471-2377-10-46

Sanders DB, Raja SM, Guptill JT, Hobson-Webb LD, Juel VC, Massey JM. The Duke myasthenia gravis clinic registry: I. Description and demographics Muscle Nerve. 2021;63(2):209–16. https://doi.org/10.1002/mus.27120.

Article  PubMed  Google Scholar 

Jaretzki A, Barohn RJ, Ernstoff RM, Kaminski HJ, Keesey JC, Penn AS, et al. Myasthenia gravis. Neurology. 2000;55(1):16–23. https://doi.org/10.1212/WNL.55.1.16.

Article  PubMed  Google Scholar 

Feng X, Huan X, Yan C, Song J, Lu J, Zhou L, et al. Adult ocular myasthenia gravis conversion: a single-center retrospective analysis in China. Eur Neurol. 2020;83(2):182–8. https://doi.org/10.1159/000507853.

Article  CAS  PubMed  Google Scholar 

Suzuki S, Murai H, Imai T, Nagane Y, Masuda M, Tsuda E, et al. Quality of life in purely ocular myasthenia in Japan. BMC Neurol. 2014;14(1):142. https://doi.org/10.1186/1471-2377-14-142.

Article  PubMed  PubMed Central  Google Scholar 

Ruff RL, Lennon VA. How myasthenia gravis alters the safety factor for neuromuscular transmission. J Neuroimmunol. 2008;201–202(C):13. https://doi.org/10.1016/J.JNEUROIM.2008.04.038

Chan KH, Lachance DH, Harper CM, Lennon VA. Frequency of seronegativity in adult-acquired generalized myasthenia gravis. Muscle Nerve. 2007;36(5):651–8. https://doi.org/10.1002/mus.20854.

Article  CAS  PubMed  Google Scholar 

Gilhus NE, Skeie GO, Romi F, Lazaridis K, Zisimopoulou P, Tzartos S. Myasthenia gravis - autoantibody characteristics and their implications for therapy. Nat Rev Neurol. 2016;12(5):259–68. https://doi.org/10.1038/nrneurol.2016.44.

Article  CAS  PubMed  Google Scholar 

Hoch W, Mcconville J, Helms S, Newsom-Davis J, Melms A, Vincent A. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med. 2001;7(3):365–8. https://doi.org/10.1038/85520.

Article  CAS  PubMed  Google Scholar 

McConville J, Farrugia ME, Beeson D, Kishore U, Metcalfe R, Newsom-Davis J, et al. Detection and characterization of MuSK antibodies in seronegative myasthenia gravis. Ann Neurol. 2004;55(4):580–4. https://doi.org/10.1002/ANA.20061.

Article  CAS  PubMed  Google Scholar 

Yan M, Liu Z, Fei E, Chen W, Lai X, Luo B, et al. Induction of anti-agrin antibodies causes myasthenia gravis in mice. Neuroscience. 2018;373:113–21. https://doi.org/10.1016/j.neuroscience.2018.01.015.

Article  CAS  PubMed  Google Scholar 

Shen C, Lu Y, Zhang B, Figueiredo D, Bean J, Jung J, et al. Antibodies against low-density lipoprotein receptor-related protein 4 induce myasthenia gravis. J Clin Invest. 2013;123. https://doi.org/10.1172/JCI66039

Tindall RSA. Humoral immunity in myasthenia gravis: biochemical characterization of acquired antireceptor antibodies and clinical correlations. Ann Neurol. 1981;10(5):437–47. https://doi.org/10.1002/ana.410100506.

Article  CAS  PubMed  Google Scholar 

Higuchi O, Hamuro J, Motomura M, Yamanashi Y. Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis. Ann Neurol. 2011;69(2):418–22. https://doi.org/10.1002/ana.22312.

Article  CAS  PubMed  Google Scholar 

• Rivner MH, Quarles BM, Pan JX, Yu Z, Howard JF, Corse A, et al. Clinical features of LRP4/agrin-antibody–positive myasthenia gravis: a multicenter study. Muscle Nerve. 2020;62(3):333. https://doi.org/10.1002/MUS.26985. Largest study on the prevalence and clinical characteristics of LRP4 and agrin antibodies.

Wang S, Yang H, Guo R, Wang L, Zhang Y, Lv J, et al. Antibodies to full-length agrin protein in Chinese patients with myasthenia gravis. Front Immunol. 2021;12. https://doi.org/10.3389/FIMMU.2021.753247

Zhang B, Shen C, Bealmear B, Ragheb S, Xiong WC, Lewis RA, et al. Autoantibodies to agrin in myasthenia gravis patients. PLoS One. 2014;9(3). https://doi.org/10.1371/JOURNAL.PONE.0091816

Mirian A, Nicolle MW, Edmond P, Budhram A. Comparison of fixed cell-based assay to radioimmunoprecipitation assay for acetylcholine receptor antibody detection in myasthenia gravis. J Neurol Sci. 2022;432:120084. https://doi.org/10.1016/J.JNS.2021.120084

Spagni G, Gastaldi M, Businaro P, Chemkhi Z, Carrozza C, Mascagna G, et al. Comparison of fixed and live cell-based assay for the detection of AChR and MuSK antibodies in myasthenia gravis. Neurol Neuroimmunol Neuroinflammation. 2023;10(1). https://doi.org/10.1212/NXI.0000000000200038

Jacob S, Viegas S, Leite MI, Webster R, Cossins J, Kennett R, et al. Presence and pathogenic relevance of antibodies to clustered acetylcholine receptor in ocular and generalized myasthenia gravis. Arch Neurol. 2012;69(8):994–10005. https://doi.org/10.1001/archneurol.2012.437.

Article  PubMed  Google Scholar 

Yang L, Maxwell S, Leite MI, Waters P, Clover L, Fan X, et al. Non-radioactive serological diagnosis of myasthenia gravis and clinical features of patients from Tianjin. China J Neurol Sci. 2011;301(1–2):71–6. https://doi.org/10.1016/J.JNS.2010.10.023.

Article  PubMed  Google Scholar 

Leite MI, Jacob S, Viegas S, Cossins J, Clover L, Morgan BP, et al. IgG1 antibodies to acetylcholine receptors in ‘seronegative’ myasthenia gravis. Brain. 2008;131(7):1940–52. https://doi.org/10.1093/BRAIN/AWN092.

Article  PubMed  PubMed Central  Google Scholar 

Cruz PMR, Al-Hajjar M, Huda S, Jacobson L, Woodhall M, Jayawant S, et al. Clinical features and diagnostic usefulness of antibodies to clustered acetylcholine receptors in the diagnosis of seronegative myasthenia gravis. JAMA Neurol. 2015;72(6):642–9. https://doi.org/10.1001/JAMANEUROL.2015.0203.

Article  Google Scholar 

Tsujihata M, Hazama R, Ishii N, Ide Y, Mori M, Takamori M. Limb muscle endplates in ocular myasthenia gravis: quantitative ultrastructural study. Neurology. 1979;29(5):654–61. https://doi.org/10.1212/WNL.29.5.654.

Article  CAS  PubMed  Google Scholar 

Spencer RF, Porter JD. Structural organization of the extraocular muscles. Rev Oculomot Res. 1988;2:33–79.

CAS  PubMed  Google Scholar 

Liu R, Xu H, Wang G, Li J, Gou L, Zhang L, et al. Extraocular muscle characteristics related to myasthenia gravis susceptibility. PLoS One. 2013;8(2). https://doi.org/10.1371/JOURNAL.PONE.0055611

Kaminski HJ, Maas E, Spiegel P, Ruff RL. Why are eye muscles frequently involved in myasthenia gravis? Neurology. 1990;40(11):1663–1663. https://doi.org/10.1212/WNL.40.11.1663.

Article  CAS  PubMed  Google Scholar 

Kaminski HJ, Li Z, Richmonds C, Lin F, Medof ME. Complement regulators in extraocular muscle and experimental autoimmune myasthenia gravis. Exp Neurol. 2004;189(2):333–42. https://doi.org/10.1016/j.expneurol.2004.06.005.

Article  CAS  PubMed  Google Scholar 

Singman EL, Matta NS, Silbert DI. Use of the Cogan lid twitch to identify myasthenia gravis. J Neuroophthalmol. 2011;31(3):239–40. https://doi.org/10.1097/WNO.0B013E3182224B92.

Article  PubMed  Google Scholar 

Apinyawasisuk S, Zhou X, Tian JJ, Garcia GA, Karanjia R, Sadun AA. Validity of forced eyelid closure test: a novel clinical screening test for ocular myasthenia gravis. J Neuro-Ophthalmology. 2017;37(3):253–7. https://doi.org/10.1097/WNO.0000000000000514.

Article  Google Scholar 

Van Stavern GP, Bhatt A, Haviland J, Black EH. A prospective study assessing the utility of Cogan’s lid twitch sign in patients with isolated unilateral or bilateral ptosis. J Neurol Sci. 2007;256(1–2):84–5. https://doi.org/10.1016/J.JNS.2007.02.020.

Article  PubMed  Google Scholar 

Benatar M. A systematic review of diagnostic studies in myasthenia gravis. Neuromuscul Disord. 2006;16(7):459–67. https://doi.org/10.1016/j.nmd.2006.05.006.

Article  PubMed  Google Scholar 

Chatzistefanou KI, Kouris T, Iliakis E, Piaditis G, Tagaris G, Katsikeris N, et al. The ice pack test in the differential diagnosis of myasthenic diplopia. Ophthalmology. 2009;116(11):2236–43. https://doi.org/10.1016/J.OPHTHA.2009.04.039.

Article  PubMed  Google Scholar 

•• Giannoccaro MP, Paolucci M, Zenesini C, Di Stasi V, Donadio V, Avoni P, et al. Comparison of ice pack test and single-fiber EMG diagnostic accuracy in patients referred for myasthenic ptosis. Neurology. 2020;95(13):e1800–6. https://doi.org/10.1212/WNL.0000000000010619. Important comparison of test characteristics of the ice pack test and SF-EMG.

Kee HJ, Yang HK, Hwang JM, Park KS. Evaluation and validation of sustained upgaze combined with the ice-pack test for ocular myasthenia gravis in Asians. Neuromuscul Disord. 2019;29(4):296–301. https://doi.org/10.1016/J.NMD.2018.12.011.

Article  PubMed  Google Scholar 

Evoli A, Tonali P, Bartoccioni E, Monaco ML. Ocular myasthenia: diagnostic and therapeutic problems. Acta Neurol Scand. 1988;77(1):31–5. https://doi.org/10.1111/J.1600-0404.1988.TB06970.X

Giannoccaro MP, Di Stasi V, Zanesini C, Donadio V, Avoni P, Liguori R. Sensitivity and specificity of single-fibre EMG in the diagnosis of ocular myasthenia varies accordingly to clinical presentation. J Neurol. 2020;267(3):739–45. https://doi.org/10.1007/S00415-019-09631-3.

Article  PubMed  Google Scholar 

Mehndiratta MM, Pandey S, Kuntzer T. Acetylcholinesterase inhibitor treatment for myasthenia gravis. Cochrane Database Syst Rev. 2014;2014(10). https://doi.org/10.1002/14651858.CD006986.PUB3

Kupersmith MJ, Ying G. Ocular motor dysfunction and ptosis in ocular myasthenia gravis: effects of treatment. Br J Ophthalmol. 2005;89(10):1330–4. https://doi.org/10.1136/BJO.2004.063404.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schneider-Gold C, Gajdos P, Toyka K V., Hohlfeld RR. Corticosteroids for myasthenia gravis. Cochrane Database Syst Rev. 2005;2011(6). https://doi.org/10.1002/14651858.CD002828.pub2

Howard FM, Duane DD, Lambert EH, Daube JR. Alternate-day prednisone: preliminary report of a double-blind controlled study. Ann NY Acad Sci. 1976;274(1):596–607. https://doi.org/10.1111/J.1749-6632.1976.TB47718.X.

Article  PubMed  Google Scholar 

Lindberg C, Andersen O, Lefvert AK. Treatment of myasthenia gravis with methylprednisolone pulse: a double blind study. Acta Neurol Scand. 1998;97(6):370–3. https://doi.org/10.1111/J.1600-0404.1998.TB05968.X.

Article  CAS  PubMed  Google Scholar 

Benatar M, Mcdermott MP, Sanders DB, Wolfe GI, Barohn RJ, Nowak RJ, et al. Efficacy of prednisone for the treatment of ocular myasthenia (EPITOME): a randomized, controlled trial. Muscle Nerve. 2016;53(3):363–9. https://doi.org/10.1002/mus.24769.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shah YS, Henderson AD, Carey AR. Effect of initial prednisone dosing on ocular myasthenia gravis control. J Neuroophthalmol. 2021;41(4):e622–6. https://doi.org/10.1097/WNO.0000000000001058.N. Retrospective study supporting the use of low-dose prednisone in OMG.

Pascuzzi RM, Coslett HB, Johns TR. Long-term corticosteriod treatment of myasthenia gravis: report of 116 patients. Ann Neurol. 1984;15(3):291–8. https://doi.org/10.1002/ANA.410150316.

Article  CAS  PubMed